ArticleBreast cancer (Tokyo, Japan)2026
Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor-positive, HER2-negative metastatic breast cancer.
Yosuke Aoyama et al.PubMed ↗Publisher ↗
No numbers read from the abstract.